SEC 13F Intelligence

Managers / Q3 2021 · view latest →

Endurant Capital Management LP

CIK 0001633055 · 66 BOVET ROAD, SUITE 353, SAN MATEO, CA, 94402 · 650-539-5905

Reported Value
$439M
Q3 2021
Positions
53
Filings on Record
24
2019–present window
Filed
Nov 15, 2021
original filing

Summary

Endurant Capital Management LP reported $439M in U.S.-listed holdings across 53 positions for Q3 2021.

Its largest position, Invacare, represents 11.7% of the portfolio.

Compared with Q2 2021, the fund opened 15 new positions and exited 19.

Portfolio Metrics

Turnover
+37.7%
vs prior filed quarter
Top-10 Concentration
+40.7%
share of reported value
Largest Position
+11.7%
Invacare
New / Exited
15 / 19
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $189MQ4 ’18Q1 ’19: $253MQ2 ’19: $254MQ3 ’19: $279MQ3 ’19Q4 ’19: $317MQ1 ’20: $221MQ2 ’20: $1.8BQ2 ’20Q3 ’20: $338MQ4 ’20: $277MQ1 ’21: $384MQ1 ’21Q2 ’21: $364MQ3 ’21: $439MQ4 ’21: $414MQ4 ’21Q1 ’22: $380MQ2 ’22: $285MQ3 ’22: $307MQ3 ’22Q4 ’22: $246MQ1 ’23: $195MQ2 ’23: $115MQ2 ’23Q3 ’23: $111MQ4 ’23: $17MQ1 ’24: $0Q1 ’24filingsflow.com

Portfolio Composition

By security type
Common Stock: 62.1%ETP: 16.8%US DOMESTIC: 11.7%Other: 6.0%ADR: 2.1%Other: 1.4%
  • Common Stock · 62.1% · $273M
  • ETP · 16.8% · $74M
  • US DOMESTIC · 11.7% · $51M
  • Other · 6.0% · $26M
  • ADR · 2.1% · $9M
  • Other · 1.4% · $6M

Quarter-over-Quarter Changes full breakdown →

vs Q2 2021 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
SPDR S&P 500 ETF TRNEW+25.3K25.3K+$74M$74M
MCKMCKESSON CORPNEW+32.6K32.6K+$6M$6M
INVACARE CORPNEW+7.00M7.00M+$6M$6M
ATRAPTARGROUP INCNEW+51.2K51.2K+$6M$6M
AHCOADAPTHEALTH CORPNEW+194.9K194.9K+$5M$5M
PKNPERKINELMER INCNEW+19.3K19.3K+$3M$3M
BDXBECTON DICKINSON & CONEW+11.1K11.1K+$3M$3M
SNYSANOFINEW+54.8K54.8K+$3M$3M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2021

47 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1INVACARE CORPNOTE 5.000%11/113.07%$57M63.73M
2ABBVABBVIE INChistory →COM4.43%$19M180.4K
3HUMHUMANA INChistory →COM3.90%$17M44.0K
4JNJJOHNSON & JOHNSONhistory →COM3.61%$16M98.1K
5HO1HOLOGIC INChistory →COM3.36%$15M200.1K
6BUWABIO RAD LABS INChistory →CL A3.10%$14M18.3K
7BMYBRISTOL-MYERS SQUIBB COhistory →COM2.85%$13M211.8K
8ICON PLCSHS2.79%$12M46.7K
9THCTENET HEALTHCARE CORPhistory →COM NEW2.71%$12M179.3K
10SIBNSI-BONE INChistory →COM2.30%$10M471.2K
118INSYNEOS HEALTH INChistory →CL A1.85%$8M92.8K
12VCYTVERACYTE INChistory →COM1.78%$8M168.2K
13CICIGNA CORP NEWhistory →COM1.65%$7M36.2K
14ELUTAZIYO BIOLOGICS INChistory →COM CL A1.51%$7M952.6K
15AVTRAVANTOR INChistory →COM1.51%$7M162.0K
16MCKMCKESSON CORPhistory →COM1.48%$6M32.6K
17ACHOWENS & MINOR INC NEWhistory →COM1.45%$6M203.8K
18RCMEURR1 RCM INChistory →COM1.42%$6M282.9K
19ATRAPTARGROUP INChistory →COM1.39%$6M51.2K
20OCULOCULAR THERAPEUTIX INChistory →COM1.39%$6M610.4K
21LABORATORY CORP AMER HLDGSCOM NEW1.21%$5M18.8K
22ADAPYADAPTIMMUNE THERAPEUTICS PLChistory →SPONDS ADR1.08%$5M917.5K
23AHCOADAPTHEALTH CORPhistory →COMMON STOCK1.03%$5M194.9K
24IM8NINSMED INChistory →COM PAR $.011.00%$4M159.9K
25SELECTA BIOSCIENCES INCCOM0.97%$4M1.02M
26MOLECULAR TEMPLATES INCCOM0.94%$4M613.6K
27BDQMALBIREO PHARMA INCCOM0.83%$4M117.3K
28PHASEURPHASEBIO PHARMACEUTICALS INCCOM0.80%$4M1.13M
29XRAYDENTSPLY SIRONA INCCOM0.80%$4M60.6K
30PKNPERKINELMER INCCOM0.76%$3M19.3K
31IOVAIOVANCE BIOTHERAPEUTICS INCCOM0.74%$3M131.1K
32PRAXIS PRECISION MEDICINES ICOM0.65%$3M153.6K
33BDXBECTON DICKINSON & COCOM0.62%$3M11.1K
34SNYSANOFISPONSORED ADR0.60%$3M54.8K
35ABGAMERISOURCEBERGEN CORPCOM0.58%$3M21.4K
36RGLSUSDREGULUS THERAPEUTICS INCCOM NEW0.56%$2M3.55M
37BLUBELLUS HEALTH INC NEWCOM NEW0.55%$2M389.8K
38DRIOEURDARIOHEALTH CORPCOM NEW0.47%$2M150.0K
39MREOMEREO BIOPHARMA GROUP PLCADS0.41%$2M746.5K
40AXSMAXSOME THERAPEUTICS INCCOM0.39%$2M52.0K
41VTLUSDIMMUNIC INCCOM0.37%$2M185.4K
42MRVIMARAVAI LIFESCIENCES HLDGS ICOM CL A0.33%$1M29.8K
43ACRSACLARIS THERAPEUTICS INCCOM0.28%$1M67.3K
44KRYSKRYSTAL BIOTECH INCCOM0.27%$1M22.9K
45BOLT1EURBOLT BIOTHERAPEUTICS INCCOM0.26%$1M90.0K
46ALLOVIR INCCOM0.25%$1M44.4K
47XENEXENON PHARMACEUTICALS INCCOM0.22%$959,00062.7K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2024$01May 7, 202413F-HRchanges · EDGAR ↗
Q4 2023$17M25Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$111M43Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$115M34Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$195M50May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$246M55Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$307M49Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$285M50Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$380M63May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$414M68Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$439M53Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$364M57Aug 27, 2021RESTATEMENTchanges · EDGAR ↗
Q1 2021$384M61May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$277M52Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$338M60Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.8B56Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$221M51May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$317M54Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$279M49Nov 25, 2019RESTATEMENTchanges · EDGAR ↗
Q2 2019$254M50Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$253M70May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$189M48Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.